8-K filing — Xenetic Biosciences, Inc. (XBIO)
Filed: 2026-08-07 AccNo: 0001683168-26-006077 Size: 228 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Xenetic Biosciences Q2 EPS $(0.41) Up From $(0.45) YoY, Sales $660.601K Up From $589.897K YoY
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.41) per share. This is a 8.89 percent increase over losses of $(0.45) per share from the same period last year. The company reported $660.601 thousand
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 1:28 PM
- Checked
- Aug 7, 2026, 1:28 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Xenetic Biosciences Announces That Its Collaboration Partner PeriNess Received Israeli Ministry Of Health Approval To Conduct An Exploratory Clinical Study Of Combination Systemic DNase I With Anti-CD19 CAR T Cells In Large B Cell Lymphoma Patients
Read original at benzingaXenetic Biosciences Reports ASCO 2026 Data Showing DNase I Boosts CAR-T Expansion And Anti-Tumor Activity In B-Cell Cancer Models
New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignanciesData highlight potential of DNase I to improve CAR-T cell
Read original at benzinga